On Wednesday, Fortinet Inc (NASDAQ:FTNT)’s shares declined -0.12% to $41.28.
Fortinet Inc (FTNT) a global leader in high-performance cyber security solutions, declared that Swisscom (SCMN.VX), the major telecom operator in Switzerland, has selected FortiGate® high performance data center firewall, FortiManager™ security administration appliance and FortiAnalyzer™ network security logging, analysis and reporting solutions to protect vital data center infrastructure. Fortinet’s ability to virtualize high performance firewall capabilities was central to Swisscom’s investment, future proofing the scale and flexibility of security for its service delivery data center.
Swisscom is the largest telecom operator in Switzerland, with over 21,000 employees and annual turnover of over 11bn EUR. The company offers mobile communications, fixed networks, Internet and digital TV services to millions of corporate and residential customers.
The security of its service delivery infrastructure is an important component of the Swisscom 2020 corporate strategy. “A key part of our long-term strategy is to build the best possible data center infrastructure for over 100 different customer-facing services, and to achieve this we’ve chosen Fortinet as our solution for high-performance firewalling,” said Gianpiero Tavano, network and security development engineer at Swisscom.
Fortinet, Inc. provides cyber security solutions for enterprises, service providers, and government organizations worldwide. The company offers FortiGate physical and virtual appliances products that provide various integrated security and networking functions to protect data, applications, and users from network- and content-level security threats; FortiManager product family to manage the system configuration and security functions of multiple FortiGate devices from a centralized console; and the FortiAnalyzer product family, which enables the collection, analysis, and archiving of content and log data generated by its products. It also offers FortiAP secure wireless access points; FortiWeb that provides security for Web-based applications; FortiMail for multi-featured messaging security; FortiDB for centrally managed database-specific security; FortiClient, an endpoint security product for desktops, laptops, and mobile devices; FortiScan for endpoint vulnerability assessment and remediation; and FortiSwitch Ethernet switches.
Starz (NASDAQ:STRZA)’s shares gained 1.03% to $45.18.
Starz (STRZA) and Chief Executive Officer, Chris Albrecht, will host a conference call to talk about results for the second quarter of 2015 on Wednesday, July 29, 2015 at 1:00 PM ET. During the call, Mr. Albrecht will talk about the company’s financial performance and may talk about future opportunities.
Starz, through its auxiliaries, operates as a media and entertainment company. It operates through Starz Networks, Starz Distribution, and Starz Animation segments. The Starz Networks segment provides premium subscription video programming to U.S. multichannel video programming distributors (MVPDs), counting cable operators, satellite television providers, and telecommunications companies. Its networks comprise Starz and Encore, which air film content, in addition to original series and specials without advertisements; and MoviePlex that offers various art house, independent films, and classic movie library content.
At the end of Wednesday’s trade, Verisign, Inc. (NASDAQ:VRSN)‘s shares surged 2.56% to $63.30.
VeriSign, Inc. (VRSN), a global leader in domain names and Internet security, declared that its earnings call for the second quarter 2015 will take place on Thursday, July 23, 2015, at 4:30 p.m. (EDT).
The earnings news release will be distributed to the wire services at about 4:05 p.m. (EDT) on Thursday, July 23, 2015, and will also be accessible directly from the company’s website at http://investor.verisign.com.
VeriSign, Inc. provides domain name registry services and Internet security worldwide. The company offers registry services that operate the authoritative directory of .com, .net, .cc, .tv, and .name domain names, in addition to the back-end systems for .gov, .jobs, .edu domain names, and others. Its registry services allow individuals and organizations to establish their online identities.
Sequenom, Inc. (NASDAQ:SQNM), ended its Wednesday’s trading session with -1.48% loss, and closed at $2.99.
Sequenom, Inc. (SQNM) the development of innovative products and services, recently declared that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been designated to the Audit and Nominating and Corporate Governance committees of the Company’s Board of Directors.
Dr. Mackey is presently the Chief Executive Officer of CYPrus Therapeutics, Inc., a privately-held small molecule pharmaceutical development company. She is a Special Advisor to Fortis Advisors LLC, and serves on the Scientific Advisory Boards of FHOOSH, Inc. and Cypher Genomics. In addition, Dr. Mackey is a director and a member of the Finance and Audit & Compliance Committees of Rady Children’s Hospital and is past-chair of CONNECT. Dr. Mackey presently serves on the boards of privately-held companies Cour Pharmaceutical Development Company (Chair), Evolve Biosystems, Inc. and Viventia Bio, Inc.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
